Jazz Pharmaceuticals, Inc. (JAZZ) Tops Q3 EPS by 11c; Issues Solid Oultook
Tweet Send to a Friend
Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) reported Q3 EPS of $1.78, $0.11 better than the analyst estimate of $1.67. Revenue for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
